Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SPRINGWORKS THERAPEUTICS, INC.

(SWTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SpringWorks Therapeutics : Seagen Working Together to Study Multiple Myeloma Combination Therapy

06/07/2021 | 08:42am EDT


ę MT Newswires 2021
All news about SPRINGWORKS THERAPEUTICS, INC.
08:01aSPRINGWORKS THERAPEUTICS : Appoints Dr. James Cassidy as Chief Medical Officer
AQ
07/21SPRINGWORKS THERAPEUTICS : HC Wainwright Adjusts SpringWorks Therapeutics' Price..
MT
07/20SPRINGWORKS THERAPEUTICS : Goldman Sachs Adjusts SpringWorks Therapeutics PT to ..
MT
07/20SPRINGWORKS THERAPEUTICS : Receives US Composition of Matter Patent to Polymorph..
MT
07/20SPRINGWORKS THERAPEUTICS : Announces Issuance of New U.S. Composition of Matter ..
AQ
06/28SECTOR UPDATE : Health Care Stocks Mixed Premarket Monday
MT
06/28PRECISION BIOSCIENCES : Doses First Patient in Study Evaluating Combination Drug..
MT
06/28SPRINGWORKS THERAPEUTICS : Precision BioSciences and SpringWorks Therapeutics Do..
BU
06/16SPRINGWORKS THERAPEUTICS : Launches Phase 1/2 Trial of Potential Low-Grade Gliom..
MT
06/16SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of ..
GL
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -131 M - -
Net cash 2021 3,17 M - -
P/E ratio 2021 -31,9x
Yield 2021 -
Capitalization 4 098 M 4 098 M -
EV / Sales 2021 -
EV / Sales 2022 368x
Nbr of Employees 98
Free-Float 76,7%
Chart SPRINGWORKS THERAPEUTICS, INC.
Duration : Period :
SpringWorks Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPRINGWORKS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 84,71 $
Average target price 113,00 $
Spread / Average Target 33,4%
EPS Revisions
Managers and Directors
Saqib Islam Chief Executive Officer & Director
Francis I. Perier Chief Financial Officer
Daniel S. Lynch Chairman
Jens Renstrup Chief Medical Officer
Michael M. Burgess Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
SPRINGWORKS THERAPEUTICS, INC.16.81%4 098
GILEAD SCIENCES, INC.18.01%86 563
BIONTECH SE251.15%69 138
WUXI APPTEC CO., LTD.28.80%67 035
REGENERON PHARMACEUTICALS19.60%59 833
VERTEX PHARMACEUTICALS-15.83%51 496